Literature DB >> 18275429

Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas.

Itziar Salaverria1, Silvia Beà, Armando Lopez-Guillermo, Virginia Lespinet, Magda Pinyol, Birgit Burkhardt, Laurence Lamant, Andreas Zettl, Doug Horsman, Randy Gascoyne, German Ott, Reiner Siebert, Georges Delsol, Elias Campo.   

Abstract

Anaplastic large cell lymphoma (ALCL) is a T/null-cell neoplasm characterized by chromosomal translocations involving the anaplastic lymphoma kinase (ALK) gene (ALK). Tumours with similar morphology and phenotype but negative for ALK have been also recognized. The secondary chromosomal imbalances of these lymphomas are not well known. We have examined 74 ALCL, 43 ALK-positive and 31 ALK-negative, cases by comparative genomic hybridization (CGH), and locus-specific alterations for TP53 and ATM were examined by fluorescence in situ hybridization and real-time quantitative polymerase chain reaction. Chromosomal imbalances were detected in 25 (58%) ALK-positive and 20 (65%) ALK-negative ALCL. ALK-positive ALCL with NPM-ALK or other ALK variant translocations showed a similar profile of secondary genetic alterations. Gains of 17p and 17q24-qter and losses of 4q13-q21, and 11q14 were associated with ALK-positive cases (P = 0.05), whereas gains of 1q and 6p21 were more frequent in ALK-negative tumours (P = 0.03). Gains of chromosome 7 and 6q and 13q losses were seen in both types of tumours. ALCL-negative tumours had a significantly worse prognosis than ALK-positive. However no specific chromosomal alterations were associated with survival. In conclusion, ALK-positive and negative ALCL have different secondary genomic aberrations, suggesting they correspond to different genetic entities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18275429     DOI: 10.1111/j.1365-2141.2007.06924.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  33 in total

Review 1.  Update: peripheral T-cell lymphomas.

Authors:  Kerry J Savage
Journal:  Curr Hematol Malig Rep       Date:  2011-12       Impact factor: 3.952

2.  Epstein-Barr virus positive anaplastic large cell lymphoma: myth or reality?

Authors:  Ly Ma; Youval Katz; Kanu P Sharan; Roland Schwarting; Annette S Kim
Journal:  Int J Clin Exp Pathol       Date:  2010-11-20

3.  MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.

Authors:  Cuiling Liu; Javeed Iqbal; Julie Teruya-Feldstein; Yulei Shen; Magdalena Julia Dabrowska; Karen Dybkaer; Megan S Lim; Roberto Piva; Antonella Barreca; Elisa Pellegrino; Elisa Spaccarotella; Cynthia M Lachel; Can Kucuk; Chun-Sun Jiang; Xiaozhou Hu; Sharathkumar Bhagavathi; Timothy C Greiner; Dennis D Weisenburger; Patricia Aoun; Sherrie L Perkins; Timothy W McKeithan; Giorgio Inghirami; Wing C Chan
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

Review 4.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

Review 5.  Survival control of malignant lymphocytes by anti-apoptotic MCL-1.

Authors:  Y Fernández-Marrero; S Spinner; T Kaufmann; P J Jost
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

Review 6.  Pharmacotherapeutic Management of Pediatric Lymphoma.

Authors:  Christine Mauz-Körholz; Natascha Ströter; Julia Baumann; Ante Botzen; Katharina Körholz; Dieter Körholz
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

7.  PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus.

Authors:  Andrew L Feldman; Mark E Law; David J Inwards; Ahmet Dogan; Rebecca F McClure; William R Macon
Journal:  Mod Pathol       Date:  2010-01-29       Impact factor: 7.842

8.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2008.

Authors:  J Han J M van Krieken
Journal:  J Hematop       Date:  2008-07       Impact factor: 0.196

Review 9.  Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.

Authors:  Fabrizio Tabbò; Maurilio Ponzoni; Raul Rabadan; Francesco Bertoni; Giorgio Inghirami
Journal:  Curr Opin Hematol       Date:  2013-07       Impact factor: 3.284

Review 10.  Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.

Authors:  Andres Morales La Madrid; Andres Morales La Madrid; Nicholas Campbell; Sonali Smith; Susan L Cohn; Ravi Salgia
Journal:  Target Oncol       Date:  2012-09-12       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.